<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00713349</url>
  </required_header>
  <id_info>
    <org_study_id>011-101-09-004</org_study_id>
    <nct_id>NCT00713349</nct_id>
    <nct_alias>NCT00693810</nct_alias>
  </id_info>
  <brief_title>Controlled Study of the Effect of Xenaderm® Ointment Vehicle Versus White Petrolatum on Healing</brief_title>
  <official_title>A Randomized, Evaluator Blinded, Controlled Study of the Effect of Xenaderm® Ointment Vehicle Versus White Petrolatum on Healing of Induced Thermal Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healthpoint</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Healthpoint</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare the healing of wounds induced by cryo-injury when
      treated with white petrolatum versus an ointment vehicle.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Wound Closure</measure>
    <time_frame>21 Days</time_frame>
    <description>Each subject acting as their own control</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Wounds</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Xenaderm Vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xenaderm Vehicle</intervention_name>
    <description>Ointment to be applied three times a day on cryo-surgery wound for 21 days.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Subject acts as own control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Ointment to be applied three times a day on cryo-surgery wound for 21 days.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Subject acts as own control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects will be considered qualified for enrollment if they:

          -  Provide written informed consent, which will consist of reading, signing, and dating
             the informed consent document after the Investigator, sub-Investigator or other
             designated study staff member has explained the study procedures, risks and contact
             information.

          -  Are male or female, ≥ 18 years of age, of any race.

          -  Are willing to attend all required study visits, and to comply with study procedures.

          -  Meet none of the exclusion criteria (any single exclusion criterion which is met by a
             potential subject will disqualify that subject from participation in this study).

        Exclusion Criteria:

        Subjects will be considered NOT qualified for enrollment if they:

          -  Have a history of dermatomyositis, systemic sclerosis, scleroderma, Sjögren's
             syndrome, systemic lupus erythematosis, discoid lupus, Ehler's Danlos disease,
             icthyosis vulgaris, vasculitis or bleeding disorders (coagulopathies).

          -  Have any dermatologic disease which may be aggravated or provoked by the wounding
             procedure, such as Lichen Planus, Psoriasis or Vitiligo.

          -  Have Fitzpatrick scale skin type 6 (never sunburns, deeply pigmented).

          -  Are at risk of keloid or hypertrophic scar formation, based on personal history,
             family history, or brief skin exam (conducted at the screening visit to look for
             keloids or hypertrophic scars).

          -  Have been treated within the last three months for uncontrolled diabetes mellitus,
             peripheral vascular disease, vitamin C deficiency, connective tissue disorders, or any
             other disease process that impedes wound healing.

          -  Are taking concomitant medications at doses which are known to interfere with healing,
             such as non-steroidal anti-inflammatory drugs, anti-neoplastic drugs, or
             immunosuppressive drugs.

          -  Are using topical glycolic acid products, alpha-hydroxy acid products, retinoids or
             chemical peel agents in the treatment areas.

          -  Are using systemic steroids or immunosuppressant agents, or have used these drugs
             within the past three months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert R Slade, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Healthpoint</affiliation>
  </overall_official>
  <overall_official>
    <last_name>D. Innes Cargill, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Healthpoint</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven R Feldman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Dermatology, Wake Forrest School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2008</study_first_submitted>
  <study_first_submitted_qc>July 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2008</study_first_posted>
  <results_first_submitted>October 9, 2013</results_first_submitted>
  <results_first_submitted_qc>October 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2013</results_first_posted>
  <last_update_submitted>October 9, 2013</last_update_submitted>
  <last_update_submitted_qc>October 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>White</keyword>
  <keyword>Petrolatum</keyword>
  <keyword>Xenaderm</keyword>
  <keyword>Vehicle</keyword>
  <keyword>Partial thickness wounds</keyword>
  <keyword>Healing</keyword>
  <keyword>Cryo-surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Petrolatum</mesh_term>
    <mesh_term>Castor Oil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy adult volunteers, 18 years of age and older</recruitment_details>
      <pre_assignment_details>Each subject acting as their own control</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vehicle vs. Placebo</title>
          <description>Xenaderm Vehicle and White Petrolatum as Placebo Comparator
Xenaderm Vehicle : Ointment to be applied three times a day on cryo-surgery wound for 21 days.
White Petrolatum : Ointment to be applied three times a day on cryo-surgery wound for 21 days
Each subject acting as their own control</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vehicle vs. Placebo</title>
          <description>Xenaderm Vehicle and White Petrolatum as Placebo Comparator
Xenaderm Vehicle : Ointment to be applied three times a day on cryo-surgery wound for 21 days.
White Petrolatum : Ointment to be applied three times a day on cryo-surgery wound for 21 days
Each subject acting as their own control</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Wound Closure</title>
        <description>Each subject acting as their own control</description>
        <time_frame>21 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Xenaderm Ointment Vehicle : each subject acting as their own control</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>White Petrolatum : each subject acting as their own control</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Wound Closure</title>
          <description>Each subject acting as their own control</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="1.1"/>
                    <measurement group_id="O2" value="14.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vehicle</title>
          <description>Xenaderm Ointment Vehicle : each subject acting as their own control</description>
        </group>
        <group group_id="E2">
          <title>Placebo Control</title>
          <description>White Petrolatum : each subject acting as their own control</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <description>Most frequently reported adverse events were in the skin and subcutaneous disorders group; most frequently reported were due to reactions to adhesive of the band-aid: erythema, itching, bleeding, burning; all were assessed unrelated to test articles.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jaime Dickerson, PhD</name_or_title>
      <organization>Smith &amp; Nephew Biotherapeutics</organization>
      <phone>817-302-3914</phone>
      <email>jaime.dickerson@smith-nephew.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

